Emmanuel Kiyonga, a Ugandan pharmacist and researcher based in South Africa, has developed a drug that may end breast cancer.
Kiyonga graduated from Sefako Makgatho Health Sciences University, South Africa, with a degree in pharmaceutical.
His innovation won him R100,000 and Studentpreneur of 2024 title. Emmanuel also made history by registering his university’s first patent.
Kiyonga’s novel formulation of Raloxifene Hydrochloride, named Raloxifene Hydrochloride Hydrate Solvate, has shown potential in treating postmenopausal osteoporosis and reducing the risk of breast cancer.
His innovation enhances the solubility and bioavailability of Raloxifene, potentially improving its therapeutic effectiveness.
Kiyonga’s research was driven by the pressing global health issues of breast cancer and osteoporosis, conditions that significantly affect postmenopausal women.
His innovation aimed to improve the therapeutic effectiveness of Raloxifene, a drug used in treating osteoporosis in postmenopausal women, which also possesses anti-cancer properties.
In 2023, at the age of 28, Kiyonga received the Young Scientist Award from the Academy of Pharmaceutical Sciences of the Pharmaceutical Society of South Africa.
This accolade was in recognition of his research project titled ‘Co-crystal Systems for Solubility Enhancement of Raloxifene HCl in Breast Cancer and Osteoporosis Therapy.
